{
    "project_id": "171279",
    "broad_study_type": "other",
    "narrow_study_type": "mechanistic_study",
    "trial_phase": "N/A",
    "observational_timeframe": "N/A",
    "justification": "Our proposal focuses on the tumour suppressor Merlin. Loss of Merlin activity leads to tumours within the brain and spinal cord. How Merlin tells cells 'do not divide' is not understood. We are using the long history of Drosophila genetics to identify proteins that interact with Merlin to help Merlin carry out its tumour suppressor functions.",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "Our ultimate goal is to understand how Merlin acts as a tumour suppressor to aid in diagnosis and therapy of Neurofibromatosis Type 2 tumours.",
    "replication_study": "no",
    "target_population_size": "N/A",
    "age_range": "unclear",
    "gender_focus": "unclear",
    "vulnerable_populations": "no",
    "rare_disease": "yes",
    "population_description": "N/A",
    "intervention_category": "N/A",
    "intervention_name": "N/A",
    "control_type": "experimental_control",
    "dose_response": "unclear",
    "combination_therapy": "no",
    "personalized_medicine": "no",
    "primary_outcome": "identification and characterization of protein partners of the Merlin tumour suppressor",
    "primary_outcome_type": "biomarker",
    "safety_focus": "no",
    "quality_of_life": "no",
    "biomarker_endpoints": "yes",
    "time_to_event": "no",
    "composite_endpoint": "no",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "no",
    "budget_impact": "no",
    "health_technology_assessment": "no",
    "resource_utilization": "no",
    "productivity_outcomes": "no",
    "implementation_science": "no",
    "policy_evaluation": "no",
    "health_system_integration": "no",
    "scalability_assessment": "no",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "no",
    "real_world_evidence": "no",
    "industry_partnership": "no",
    "patient_engagement": "no",
    "community_based": "no",
    "indigenous_collaboration": "no",
    "international_collaboration": "no",
    "international_network": "no",
    "regulatory_pathway": "no",
    "ethics_focus": "no",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "cancer",
    "disease_stage": "unclear",
    "comorbidity_focus": "no",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "no",
    "health_equity": "no",
    "climate_health": "no",
    "urban_rural": "unclear",
    "biobank_use": "no",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "long_term",
    "multicenter": "no",
    "healthcare_setting": "laboratory",
    "disease_area": "Neurofibromatosis Type 2",
    "methodology_innovation": "using Drosophila genetics to identify and characterize protein partners of the Merlin tumour suppressor",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "no"
} 